{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:50:35Z","timestamp":1791899435797,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T00:00:00Z","timestamp":1533513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T00:00:00Z","timestamp":1533513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The study was funded by Collegium Medicum of Nicolaus Copernicus University [NCU CM Grant no. 202] and did not receive any external funding."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its antiplatelet action. Still, ticagrelor is extensively metabolized by hepatic CYP3A enzymes, and AR-C124910XX is its only active metabolite. A post hoc analysis of patient-level (n\u2009=\u2009117) pharmacokinetic data pooled from two prospective studies was performed to identify clinical characteristics affecting the degree of AR-C124910XX formation during the first six hours after 180\u2009mg ticagrelor loading dose in the setting of ACS. Both linear and multiple regression analyses indicated that ACS patients presenting with ST-elevation myocardial infarction or suffering from diabetes mellitus are more likely to have decreased rate of ticagrelor metabolism during the acute phase of ACS. Administration of morphine during ACS was found to negatively influence transformation of ticagrelor into AR-C124910XX when assessed with linear regression analysis, but not with multiple regression analysis. On the other hand, smoking appears to increase the degree of ticagrelor transformation in ACS patients. Mechanisms underlying our findings and their clinical significance warrant further research.<\/jats:p>","DOI":"10.1038\/s41598-018-29619-9","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T10:13:38Z","timestamp":1533032018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Metabolism of ticagrelor in patients with acute coronary syndromes"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-0987","authenticated-orcid":false,"given":"Piotr","family":"Adamski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Buszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Niezgoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malwina","family":"Bara\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Ostrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Paciorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliano P.","family":"Navarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Kubica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,6]]},"reference":[{"key":"29619_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1056\/NEJMe038191","volume":"350","author":"RA Lange","year":"2004","unstructured":"Lange, R. A. & Hillis, L. D. Antiplatelet therapy for ischemic heart disease. N Engl J Med. 350, 277\u2013280 (2004).","journal-title":"N Engl J Med."},{"key":"29619_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","volume":"58","author":"SS Brar","year":"2011","unstructured":"Brar, S. S. et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 58, 1945\u20131954 (2011).","journal-title":"J Am Coll Cardiol."},{"key":"29619_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez, B. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 39, 119\u2013177 (2018).","journal-title":"Eur Heart J."},{"key":"29619_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi, M. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 37, 267\u2013315 (2016).","journal-title":"Eur Heart J."},{"key":"29619_CR5","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742cf6","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara, P. T. et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 127, e362\u2013425 (2013).","journal-title":"Circulation."},{"key":"29619_CR6","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/CIR.0000000000000134","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam, E. A. et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 130, e344\u2013426 (2014).","journal-title":"Circulation."},{"key":"29619_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1160\/TH13-11-0915","volume":"112","author":"P Adamski","year":"2014","unstructured":"Adamski, P. et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost. 112, 224\u2013242 (2014).","journal-title":"Thromb Haemost."},{"key":"29619_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"S Husted","year":"2006","unstructured":"Husted, S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 27, 1038\u20131047 (2006).","journal-title":"Eur Heart J."},{"key":"29619_CR9","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1124\/dmd.110.032250","volume":"38","author":"R Teng","year":"2010","unstructured":"Teng, R., Oliver, S., Hayes, M. A. & Butler, K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 38, 1514\u20131521 (2010).","journal-title":"Drug Metab Dispos."},{"key":"29619_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00228-009-0778-5","volume":"66","author":"R Teng","year":"2010","unstructured":"Teng, R. & Butler, K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 66, 487\u2013496 (2010).","journal-title":"Eur J Clin Pharmacol."},{"key":"29619_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/11599830-000000000-00000","volume":"51","author":"SE Husted","year":"2012","unstructured":"Husted, S. E. et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet. 51, 397\u2013409 (2012).","journal-title":"Clin Pharmacokinet."},{"key":"29619_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","volume":"54","author":"R Teng","year":"2015","unstructured":"Teng, R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet. 54, 1125\u20131138 (2015).","journal-title":"Clin Pharmacokinet."},{"key":"29619_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","volume":"37","author":"J Kubica","year":"2016","unstructured":"Kubica, J. et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 37, 245\u2013252 (2016).","journal-title":"Eur Heart J."},{"key":"29619_CR14","doi-asserted-by":"publisher","first-page":"e0186013","DOI":"10.1371\/journal.pone.0186013","volume":"12","author":"P Adamski","year":"2017","unstructured":"Adamski, P. et al. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: a prospective, observational, single-centre study. PLoS One. 12, e0186013 (2017).","journal-title":"PLoS One."},{"key":"29619_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1160\/TH16-07-0535","volume":"116","author":"M Kozi\u0144ski","year":"2016","unstructured":"Kozi\u0144ski, M. et al. Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? The HARMONIC study. Thromb Haemost. 116, 1140\u20131149 (2016).","journal-title":"Thromb Haemost."},{"key":"29619_CR16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.jcin.2015.02.030","volume":"8","author":"F Franchi","year":"2015","unstructured":"Franchi, F. et al. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. JACC Cardiovasc Interv. 8, 1457\u20131467 (2015).","journal-title":"JACC Cardiovasc Interv."},{"key":"29619_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijcard.2016.04.077","volume":"215","author":"J Kubica","year":"2016","unstructured":"Kubica, J. et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 215, 201\u2013208 (2016).","journal-title":"Int J Cardiol."},{"key":"29619_CR18","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/dmd.110.037143","volume":"39","author":"D Zhou","year":"2011","unstructured":"Zhou, D., Andersson, T. B. & Grimm, S. W. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 39, 703\u2013710 (2011).","journal-title":"Drug Metab Dispos."},{"key":"29619_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00228-012-1436-x","volume":"69","author":"R Teng","year":"2013","unstructured":"Teng, R., Mitchell, P. & Butler, K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Eur J Clin Pharmacol. 69, 877\u2013883 (2013).","journal-title":"Eur J Clin Pharmacol."},{"key":"29619_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/21556660.2013.785413","volume":"2","author":"R Teng","year":"2013","unstructured":"Teng, R. & Butler, K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2, 30\u201339 (2013).","journal-title":"J Drug Assess."},{"key":"29619_CR21","first-page":"100","volume":"3","author":"P Adamski","year":"2015","unstructured":"Adamski, P. et al. Does morphine administration affect ticagrelor conversion to its active metabolite in patients with acute myocardial infarction? A sub-analysis of the randomized, double-blind, placebo-controlled IMPRESSION trial. Folia Med Copernicana. 3, 100\u2013106 (2015).","journal-title":"Folia Med Copernicana."},{"key":"29619_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jth.12445","volume":"12","author":"JM Siller-Matula","year":"2014","unstructured":"Siller-Matula, J. M., Trenk, D., Kr\u00e4henb\u00fchl, S., Michelson, A. D. & Delle-Karth, G. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost. 12, 2\u201313 (2014).","journal-title":"J Thromb Haemost."},{"key":"29619_CR23","doi-asserted-by":"publisher","first-page":"e013218","DOI":"10.1136\/bmjopen-2016-013218","volume":"7","author":"P Adamski","year":"2017","unstructured":"Adamski, P. et al. Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study. BMJ Open. 7, e013218 (2017).","journal-title":"BMJ Open."},{"key":"29619_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5603\/MRJ.2016.0002","volume":"1","author":"P Niezgoda","year":"2016","unstructured":"Niezgoda, P. et al. Impact of ticagrelor administration strategy on its pharmacokinetics and pharmacodynamics in patients with unstable angina pectoris: a protocol of a randomized study. Med Res J. 1, 10\u201314 (2016).","journal-title":"Med Res J."},{"key":"29619_CR25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1160\/TH16-08-0670","volume":"117","author":"P Niezgoda","year":"2017","unstructured":"Niezgoda, P. et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic\/pharmacodynamic study. Thromb Haemost. 117, 718\u2013726 (2017).","journal-title":"Thromb Haemost."},{"key":"29619_CR26","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1093\/eurheartj\/ehs184","volume":"33","author":"K Thygesen","year":"2012","unstructured":"Thygesen, K. et al. Third universal definition of myocardial infarction. Eur Heart J. 33, 2551\u20132567 (2012).","journal-title":"Eur Heart J."},{"key":"29619_CR27","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs289","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg, P. G. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 33, 2569\u20132619 (2012).","journal-title":"Eur Heart J."},{"key":"29619_CR28","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.jchromb.2010.06.018","volume":"878","author":"H Sill\u00e9n","year":"2010","unstructured":"Sill\u00e9n, H., Cook, M. & Davis, P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 878, 2299\u20132306 (2010).","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"29619_CR29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00228-012-1227-4","volume":"68","author":"R Teng","year":"2012","unstructured":"Teng, R., Mitchell, P. & Butler, K. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Eur J Clin Pharmacol. 68, 1175\u20131182 (2012).","journal-title":"Eur J Clin Pharmacol."},{"key":"29619_CR30","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1177\/0091270011415526","volume":"52","author":"K Butler","year":"2012","unstructured":"Butler, K. & Teng, R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 52, 1388\u20131398 (2012).","journal-title":"J Clin Pharmacol."},{"key":"29619_CR31","doi-asserted-by":"publisher","first-page":"666","DOI":"10.5414\/CP202549","volume":"54","author":"J Li","year":"2016","unstructured":"Li, J., Tang, W., Storey, R. F., Husted, S. & Teng, R. Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Int J Clin Pharmacol Ther. 54, 666\u2013674 (2016).","journal-title":"Int J Clin Pharmacol Ther."},{"key":"29619_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","volume":"65","author":"G Parodi","year":"2015","unstructured":"Parodi, G. et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 65, 511\u2013512 (2015).","journal-title":"J Am Coll Cardiol."},{"key":"29619_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-015-0320-0","volume":"55","author":"D Alexopoulos","year":"2016","unstructured":"Alexopoulos, D. et al. Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic\/Pharmacodynamic Study. Clin Pharmacokinet. 55, 359\u2013367 (2016).","journal-title":"Clin Pharmacokinet."},{"key":"29619_CR34","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","volume":"36","author":"D Aradi","year":"2015","unstructured":"Aradi, D. et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 36, 1762\u20131771 (2015).","journal-title":"Eur Heart J."},{"key":"29619_CR35","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/eurheartj\/ehv116","volume":"36","author":"C Varenhorst","year":"2015","unstructured":"Varenhorst, C. et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 36, 1901\u20131912 (2015).","journal-title":"Eur Heart J."},{"key":"29619_CR36","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1177\/0091270010379409","volume":"51","author":"K Butler","year":"2011","unstructured":"Butler, K. & Teng, R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. J Clin Pharmacol. 51, 978\u2013987 (2011).","journal-title":"J Clin Pharmacol."},{"key":"29619_CR37","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","volume":"61","author":"G Parodi","year":"2013","unstructured":"Parodi, G. et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 61, 1601\u20131606 (2013).","journal-title":"J Am Coll Cardiol."},{"key":"29619_CR38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","volume":"84","author":"HS Smith","year":"2009","unstructured":"Smith, H. S. Opioid metabolism. Mayo Clin Proc. 84, 613\u2013624 (2009).","journal-title":"Mayo Clin Proc."},{"key":"29619_CR39","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","volume":"122","author":"PG Steg","year":"2010","unstructured":"Steg, P. G. et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 122, 2131\u20132141 (2010).","journal-title":"Circulation."},{"key":"29619_CR40","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/eurheartj\/ehu160","volume":"35","author":"D Lindholm","year":"2014","unstructured":"Lindholm, D. et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 35, 2083\u20132093 (2014).","journal-title":"Eur Heart J."},{"key":"29619_CR41","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","volume":"31","author":"S James","year":"2010","unstructured":"James, S. et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 31, 3006\u20133016 (2010).","journal-title":"Eur Heart J."},{"key":"29619_CR42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ahj.2012.06.005","volume":"164","author":"JH Cornel","year":"2012","unstructured":"Cornel, J. H. et al. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 164, 334\u2013342.e1 (2012).","journal-title":"Am Heart J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29619-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29619-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29619-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T08:22:35Z","timestamp":1671610955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29619-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["29619"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-29619-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,6]]},"assertion":[{"value":"23 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A. received honorarium for a lecture from AstraZeneca and J.K. received a consulting fee from AstraZeneca. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11746"}}